Mon, May 12, 3:39 PM (37 days ago)
**Endo, Inc. (NDOI) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** $392.8 million, down 6% from $419.5 million in Q1 2024 due to competitive pressures in Sterile Injectables and Generic Pharmaceuticals segments, partially offset by growth in Branded Pharmaceuticals. - **Net Loss:** $128.6 million, slightly improved from $154.2 million in Q1 2024. - **Gross Margin:** 24.8%, down from 52.6% in Q1 2024, primarily due to amortization of inventory step-up and competitive pressures. - **Operating Cash Flow:** $1.1 million, down from $25.8 million in Q1 2024, reflecting operational challenges and timing of cash collections. **Segment Performance:** - **Branded Pharmaceuticals:** Revenue up 4% to $209.5 million, driven by XIAFLEX® and SUPPRELIN® LA. - **Sterile Injectables:** Revenue down 27% to $71.3 million due to competitive pressures on ADRENALIN® and VASOSTRICT®. - **Generic Pharmaceuticals:** Revenue down 4% to $99.1 million due to competitive pressures. - **International Pharmaceuticals:** Revenue down 24% to $13.0 million. **Cash Flow and Liquidity:** - **Cash and Cash Equivalents:** $369.7 million, down from $387.2 million in Q4 2024. - **Working Capital:** $963.1 million, up from $960.9 million in Q4 2024. - **Debt:** $2.4 billion in long-term debt, with $396 million of revolving credit facility undrawn. **Future Operations and Uncertainties:** - **Mallinckrodt Combination:** Expected to close in H2 2025, with Mallinckrodt as the parent entity. - **International Pharmaceuticals Divestiture:** Expected to close in mid-2025, with up to $99 million in total consideration. - **Legal and Regulatory Risks:** Ongoing legal proceedings and regulatory uncertainties may impact financial results. - **Inflation and Supply Chain:** Inflation and supply chain disruptions may affect costs and operations. **Trends and Outlook:** - Endo continues to face competitive pressures and operational challenges. - Strategic initiatives, including the Mallinckrodt combination and divestitures, aim to strengthen the company's financial position. - Future performance will depend on market conditions, regulatory environment, and successful execution of strategic plans.